Floatz logo

Moma-341

MSI-H Cancer

MOMA TherapeuticsPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the MSI-H Cancer cohort.

Asset / SponsorPhaseRating
Tiragolumab
University Medical Center Groningen
Phase 2CCC
Atezolizumab
University Medical Center Groningen
Phase 2CCC
Ndi-219216
Nimbus Wadjet, Inc.
Phase 1/2CC
Decoy20
Indaptus Therapeutics, Inc
Phase 1/2CC
Pyrotinib
Indaptus Therapeutics, Inc
Phase 1/2CC

View all 11 →

Same molecule, other indications

Moma-341 is also rated in:

Lynch syndromeDormant
CC
Indicative ·
43 / 100
View asset →
Metastatic Solid TumorDormant
C
Indicative ·
37 / 100
View asset →
endometrial carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →